Ziopharm Oncology Inc. (NASDAQ:ZIOP)’s share price traded up 5.3% on Monday . The stock traded as high as $5.21 and last traded at $5.12, with a volume of 971,009 shares trading hands. The stock had previously closed at $4.86.

Several equities analysts have commented on the stock. Zacks Investment Research raised shares of Ziopharm Oncology from a “hold” rating to a “buy” rating and set a $5.50 target price on the stock in a research report on Wednesday, July 27th. Mizuho reissued a “neutral” rating and set a $5.00 target price (down previously from $7.00) on shares of Ziopharm Oncology in a research report on Monday, July 18th. Wells Fargo & Co. reissued an “underperform” rating on shares of Ziopharm Oncology in a research report on Friday, July 15th. Griffin Securities reissued a “buy” rating and set a $21.00 target price on shares of Ziopharm Oncology in a research report on Friday, July 1st. Finally, Raymond James Financial Inc. assumed coverage on shares of Ziopharm Oncology in a research report on Thursday, June 2nd. They set a “market perform” rating on the stock. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $9.55.

The stock has a 50 day moving average of $5.55 and a 200 day moving average of $6.78. The company’s market capitalization is $658.89 million.

Ziopharm Oncology (NASDAQ:ZIOP) last announced its quarterly earnings results on Tuesday, May 10th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.01. The company had revenue of $1.97 million for the quarter, compared to the consensus estimate of $1.89 million. Ziopharm Oncology’s revenue for the quarter was up 623.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.69) EPS. Equities research analysts expect that Ziopharm Oncology Inc. will post ($0.42) earnings per share for the current year.

Other institutional investors recently made changes to their positions in the company. Morgan Stanley boosted its position in shares of Ziopharm Oncology by 5.1% in the fourth quarter. Morgan Stanley now owns 1,618,205 shares of the biotechnology company’s stock valued at $13,447,000 after buying an additional 78,583 shares in the last quarter. California State Teachers Retirement System boosted its position in shares of Ziopharm Oncology by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 212,521 shares of the biotechnology company’s stock valued at $1,766,000 after buying an additional 3,354 shares in the last quarter. Swiss National Bank boosted its position in shares of Ziopharm Oncology by 2.2% in the fourth quarter. Swiss National Bank now owns 159,220 shares of the biotechnology company’s stock valued at $1,323,000 after buying an additional 3,500 shares in the last quarter. Finally, California Public Employees Retirement System boosted its position in shares of Ziopharm Oncology by 567.2% in the fourth quarter. California Public Employees Retirement System now owns 307,366 shares of the biotechnology company’s stock valued at $2,554,000 after buying an additional 261,300 shares in the last quarter.

ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.